Singapore-based RNA technology firm Mirxes has secured US$40 million in structured financing from CBC Group’s R-Bridge Healthcare Fund.

The funding will help the company expand globally, focusing on high-growth markets in the Asia-Pacific region, including Southeast Asia, China, and Japan.

R-Bridge, which is Asia’s first healthcare-focused structured financing fund, provides solutions for life sciences companies backed by royalties and cash flows.

This synthetic royalty-backed transaction will enable Mirxes to advance its RNA diagnostic technologies and meet its strategic priorities.

Mirxes specializes in cancer early detection and produces GastroClear, a non-invasive blood-based diagnostic test for gastric cancer.

It is the first In Vitro Diagnostics product to receive regulatory approval in this category worldwide.

Recent Mirxes developments